Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 63 citing Ceglia: Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes.... (0.09 sec) 

Update in type 1 diabetes

- endojournals.org
GS Eisenbarth - Journal of Clinical Endocrinology & Metabolism, 2007 - Endocrine Soc
Synthesis: There has been recent progress in defining the genetics,
pathogenesis, and natural history of the disease. In addition, there is a major
effort to develop immunotherapies to prevent the disorder and to cure the ...
Cited by 30 - Related articles - All 3 versions

Cross-sectional and prospective study of lung function in adults with type 2 diabetes

- diabetesjournals.org
HC Yeh, NM Punjabi, NY Wang, JS Pankow, BB … - Diabetes Care, 2008 - Am Diabetes Assoc
RESULTS—At baseline, adults with diabetes had significantly lower predicted
FVC (96 vs. 103%, P < 0.001) and predicted FEV 1 (92 vs. 96%, P < 0.001) than
those without diabetes. These differences remained significant after ...
Cited by 14 - Related articles - BL Direct - All 7 versions

[PDF] Inhaled insulin: extending the horizons of inhalation therapy


VP Guntur, R Dhand - Respiratory care, 2007 - rtjournalonline.com
Targeted glycemic control in patients with type 1 and type 2 diabetes is grossly
inadequate, despite data demonstrating reduced microvascular and macrovascular
diabetic complications with inten- sive treatment. A significant proportion ...
Cited by 11 - Related articles - View as HTML - BL Direct - All 5 versions

[PDF] Terapêutica clínica–Insulina inalada para a diabetes mellitus Clinical therapeutics–Inhaled …


GT McMahon, RA Arky - N Engl J Med, 2007 - scielo.oces.mctes.pt
Resumo A propósito de um doente com diabetes mellitus (DM) tipo 2, com controlo
glicémico insuficiente com agen- tes orais, é feita uma recomendação
terapêutica baseada na discussão clínica e no mecanismo de benefício de ...
Cited by 27 - Related articles - View as HTML - BL Direct - All 14 versions

Pulmonary function changes related to acute and chronic administration of inhaled insulin


M Hegewald, RO Crapo, RL Jensen - Diabetes Technology & Therapeutics, 2007 - liebertonline.com
The need for frequent insulin injections to achieve optimal glycemic control
remains a major barrier to initiating and maintaining insulin therapy in
diabetes. The inhaled route of insulin ad- ministration offers many ...
Cited by 9 - Related articles - BL Direct - All 3 versions

Recent advances in insulin treatment of children


AK Steck, GJ Klingensmith, R Fiallo-Scharer - Pediatric Diabetes, 2007 - interscience.wiley.com
Abstract: Since the findings of the Diabetes Control and Complications Trial
became public in 1993, intensive insulin therapy has been recommended for all
children. However, successful implementation remains a challenge because of ...
Cited by 7 - Related articles - BL Direct - All 3 versions

Lung function changes related to diabetes mellitus

- utsouthwestern.edu [PDF] 
CCW Hsia, P Raskin - Diabetes Technology & Therapeutics, 2007 - liebertonline.com
Diabetic microangiopathy targets the lung as it does other organs. Even though
respiratory dysfunction in most patients with diabetes is subclinical and rarely
the presenting complaint, there are several reasons why pulmonary ...
Cited by 7 - Related articles - BL Direct - All 9 versions

Developing a pulmonary insulin delivery system for patients with diabetes


G Dailey - Clinical therapeutics, 2007 - Elsevier
Results: Eight clinical studies to date have reported that IDPI consistently
improved glycemic control, whether used in combination with longer-acting SC
insulin regimens in patients with type 1 or type 2 DM or to supplement or ...
Cited by 6 - Related articles - All 3 versions

Why is Exubera being withdrawn?


CJ Bailey, AH Barnett - British Medical Journal, 2007 - bmj.com
On 18 October Pfizer announced that it would withdraw the first inhaled insulin,
Exubera, from the market, as sales were too low. In January 2006 Pfizer bought
the worldwide rights to Exubera from Sanofi-Aventis for $1.3bn (£0.6bn; ...
Cited by 6 - Related articles - BL Direct - All 2 versions

Inhaled insulin: gone with the wind?


C Mathieu, EAM Gale - Diabetologia, 2008 - Springer
Yesterday it was going to sweep the world; today it is gone. Exubera is no more:
there was no money in it. As for the patients who volunteered to test the new
therapy, and those to whom it has offered a new lease of life: tough luck. ...
Cited by 5 - Related articles - BL Direct - All 3 versions


Result Page: 

1

2

3

4

5

6

7

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google